FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response.	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Bray June					2. Issuer Name <b>and</b> Ticker or Trading Symbol BioXcel Therapeutics, Inc. [ BTAI ]								5. Relationship of Reporting Person Check all applicable) X Director				ner		
	XCEL TH	ERAPEUTICS, 1	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/01/2021								Offi bel	cer (give title w)		Other (s below)	pecify	
555 LONG WHARF DRIVE					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) NEW HA	WEN C	Т	06511											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,		e, Transaction Disposed O Code (Instr. 5)		ties Acquired (A) or d Of (D) (Instr. 3, 4 a		I Secu Bene	icially d Following	Form (D) o	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	(A) or (D)	Price	Trans	action(s) 3 and 4)			Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any				ransaction of E ode (Instr. Derivative (I			Expiration Date (Month/Day/Year) S			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price Derivati Security (Instr. 5)		e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	Date Expiration						Amount or Number of Shares							
Stock Option (Right to Buy)	\$55.71	03/01/2021			A		4,167		(1)	03	3/01/2021	Common Stock	4,167	\$0	4,167	7	D		

## **Explanation of Responses:**

1. The option vests and becomes exercisable on the earlier of the earlier of the first anniversary of March 1, 2021 or the day immediately prior to the start of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through the vesting date.

/s/ Richard Steinhart, as Attorney-in-Fact for June Bray

03/03/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.